TherapeuticsMD (TXMD)
Market Price (10/16/2026): $1.93 | Market Cap: $22.3 MilSector: Health Care | Industry: Pharmaceuticals
TherapeuticsMD (TXMD)
Market Price (10/16/2026): $1.93Market Cap: $22.3 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 96%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 96% Attractive yieldFCF Yield is 14% | Weak multi-year price returns2Y Excs Rtn is -10%, 3Y Excs Rtn is -108% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -118% Weak revenue growthRev Chg QQuarterly Revenue Change % is -8.7% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.8% Key risksTXMD key risks include [1] severe financial distress, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 96%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 96% |
| Attractive yieldFCF Yield is 14% |
| Weak multi-year price returns2Y Excs Rtn is -10%, 3Y Excs Rtn is -108% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -118% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -8.7% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.8% |
| Key risksTXMD key risks include [1] severe financial distress, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 10/1/2026
TherapeuticsMD (TXMD) stock has lost about 15% since 6/30/2026 because of the following key factors:
1. TherapeuticsMD reported a significant revenue miss for fiscal Q2 2026, which ended on June 30, 2026. The company announced its Q2 2026 results on August 11, 2026, reporting quarterly revenue of $0.87 million, substantially missing the consensus estimate of $19.77 million. This large discrepancy between actual and expected revenue likely contributed to investor concern.
2. The company experienced a decline in its core license revenue and net income in fiscal Q2 2026. TherapeuticsMD, which operates as a pharmaceutical royalty company, saw its license revenue decrease by approximately 9.2% to $864,000 in Q2 2026 compared to $952,000 in Q2 2025. Concurrently, net income from continuing operations plummeted by 69.9% to $164,000, down from $545,000 in the prior year's comparable quarter. This indicated a weakening performance in its primary business model.
Show more
TherapeuticsMD (TXMD) stock has lost about 15% since 6/30/2026 because of the following key factors:
1. TherapeuticsMD reported a significant revenue miss for fiscal Q2 2026, which ended on June 30, 2026. The company announced its Q2 2026 results on August 11, 2026, reporting quarterly revenue of $0.87 million, substantially missing the consensus estimate of $19.77 million. This large discrepancy between actual and expected revenue likely contributed to investor concern.
2. The company experienced a decline in its core license revenue and net income in fiscal Q2 2026. TherapeuticsMD, which operates as a pharmaceutical royalty company, saw its license revenue decrease by approximately 9.2% to $864,000 in Q2 2026 compared to $952,000 in Q2 2025. Concurrently, net income from continuing operations plummeted by 69.9% to $164,000, down from $545,000 in the prior year's comparable quarter. This indicated a weakening performance in its primary business model.
Show more
Updated on 10/1/2026
TherapeuticsMD (TXMD) stock has lost about 15% since 6/30/2026 because of the following key factors:
1. TherapeuticsMD reported a significant revenue miss for fiscal Q2 2026, which ended on June 30, 2026. The company announced its Q2 2026 results on August 11, 2026, reporting quarterly revenue of $0.87 million, substantially missing the consensus estimate of $19.77 million. This large discrepancy between actual and expected revenue likely contributed to investor concern.
2. The company experienced a decline in its core license revenue and net income in fiscal Q2 2026. TherapeuticsMD, which operates as a pharmaceutical royalty company, saw its license revenue decrease by approximately 9.2% to $864,000 in Q2 2026 compared to $952,000 in Q2 2025. Concurrently, net income from continuing operations plummeted by 69.9% to $164,000, down from $545,000 in the prior year's comparable quarter. This indicated a weakening performance in its primary business model.
3. Operating expenses continued to outpace recurring revenue, coupled with uncertainty from an ongoing strategic review. For fiscal Q2 2026, total operating expenses were $1.685 million, an increase of $38 thousand from Q2 2025. This sustained high expense base, exceeding recurring license revenue, increased the company's reliance on less predictable milestone payments. Adding to investor apprehension, TherapeuticsMD is undergoing an "open-ended strategic review exploring potential mergers or asset sales without a guaranteed outcome or confirmed Nasdaq listing stability," introducing significant future uncertainty.
Show less
TherapeuticsMD (TXMD) stock has lost about 15% since 6/30/2026 because of the following key factors:
1. TherapeuticsMD reported a significant revenue miss for fiscal Q2 2026, which ended on June 30, 2026. The company announced its Q2 2026 results on August 11, 2026, reporting quarterly revenue of $0.87 million, substantially missing the consensus estimate of $19.77 million. This large discrepancy between actual and expected revenue likely contributed to investor concern.
2. The company experienced a decline in its core license revenue and net income in fiscal Q2 2026. TherapeuticsMD, which operates as a pharmaceutical royalty company, saw its license revenue decrease by approximately 9.2% to $864,000 in Q2 2026 compared to $952,000 in Q2 2025. Concurrently, net income from continuing operations plummeted by 69.9% to $164,000, down from $545,000 in the prior year's comparable quarter. This indicated a weakening performance in its primary business model.
3. Operating expenses continued to outpace recurring revenue, coupled with uncertainty from an ongoing strategic review. For fiscal Q2 2026, total operating expenses were $1.685 million, an increase of $38 thousand from Q2 2025. This sustained high expense base, exceeding recurring license revenue, increased the company's reliance on less predictable milestone payments. Adding to investor apprehension, TherapeuticsMD is undergoing an "open-ended strategic review exploring potential mergers or asset sales without a guaranteed outcome or confirmed Nasdaq listing stability," introducing significant future uncertainty.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -12.7% change in TXMD stock from 6/30/2026 to 10/15/2026 was primarily driven by a -10.5% change in the company's P/S Multiple.| (LTM values as of) | 6302026 | 10152026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.21 | 1.93 | -12.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | -2.5% |
| P/S Multiple | 7.6 | 6.8 | -10.5% |
| Shares Outstanding (Mil) | 12 | 12 | 0.0% |
| Cumulative Contribution | -12.7% |
Market Drivers
6/30/2026 to 10/15/2026| Return | Correlation | |
|---|---|---|
| TXMD | -12.7% | |
| Market (SPY) | 3.4% | -13.7% |
| Sector (XLV) | 11.7% | 18.5% |
Fundamental Drivers
The -4.5% change in TXMD stock from 3/31/2026 to 10/15/2026 was primarily driven by a -11.7% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 10152026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.02 | 1.93 | -4.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | 8.2% |
| P/S Multiple | 7.7 | 6.8 | -11.7% |
| Shares Outstanding (Mil) | 12 | 12 | 0.0% |
| Cumulative Contribution | -4.5% |
Market Drivers
3/31/2026 to 10/15/2026| Return | Correlation | |
|---|---|---|
| TXMD | -4.5% | |
| Market (SPY) | 19.0% | -1.8% |
| Sector (XLV) | 21.4% | 11.7% |
Fundamental Drivers
The 79.5% change in TXMD stock from 9/30/2025 to 10/15/2026 was primarily driven by a 40.5% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 10152026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.07 | 1.93 | 79.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | 27.8% |
| P/S Multiple | 4.9 | 6.8 | 40.5% |
| Shares Outstanding (Mil) | 12 | 12 | 0.0% |
| Cumulative Contribution | 79.5% |
Market Drivers
9/30/2025 to 10/15/2026| Return | Correlation | |
|---|---|---|
| TXMD | 79.5% | |
| Market (SPY) | 16.8% | 2.9% |
| Sector (XLV) | 29.0% | 12.9% |
Fundamental Drivers
The -36.1% change in TXMD stock from 9/30/2023 to 10/15/2026 was primarily driven by a -95.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302023 | 10152026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.02 | 1.93 | -36.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 70 | 3 | -95.3% |
| P/S Multiple | 0.4 | 6.8 | 1444.4% |
| Shares Outstanding (Mil) | 10 | 12 | -11.7% |
| Cumulative Contribution | -36.1% |
Market Drivers
9/30/2023 to 10/15/2026| Return | Correlation | |
|---|---|---|
| TXMD | -36.1% | |
| Market (SPY) | 86.7% | 11.5% |
| Sector (XLV) | 44.1% | 11.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TXMD Return | -71% | -69% | -60% | -62% | 90% | 21% | -97% |
| Peers Return | 29% | 0% | -30% | 1% | -9% | 25% | 4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 14% | 108% |
Monthly Win Rates [3] | |||||||
| TXMD Win Rate | 8% | 33% | 17% | 42% | 42% | 60% | |
| Peers Win Rate | 57% | 47% | 35% | 45% | 50% | 62% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| TXMD Max Drawdown | -86% | -91% | -68% | -68% | -54% | -34% | |
| Peers Max Drawdown | -27% | -32% | -45% | -33% | -36% | -33% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: OGN, ABBV, PFE, MRK, DARE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/15/2026 (YTD)
How Low Can It Go
| Event | TXMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -28.9% | -18.8% |
| % Gain to Breakeven | 40.7% | 23.1% |
| Time to Breakeven | 13 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -63.8% | -33.7% |
| % Gain to Breakeven | 176.2% | 50.9% |
| Time to Breakeven | 300 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -43.3% | -3.7% |
| % Gain to Breakeven | 76.3% | 3.9% |
| Time to Breakeven | 100 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -16.4% | -12.2% |
| % Gain to Breakeven | 19.7% | 13.9% |
| Time to Breakeven | 7 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -35.7% | -6.8% |
| % Gain to Breakeven | 55.5% | 7.3% |
| Time to Breakeven | 87 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -22.7% | -0.2% |
| % Gain to Breakeven | 29.4% | 0.2% |
| Time to Breakeven | 21 days | 1 days |
In The Past
TherapeuticsMD's stock fell -28.9% during the 2025 US Tariff Shock. Such a loss loss requires a 40.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TXMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -28.9% | -18.8% |
| % Gain to Breakeven | 40.7% | 23.1% |
| Time to Breakeven | 13 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -63.8% | -33.7% |
| % Gain to Breakeven | 176.2% | 50.9% |
| Time to Breakeven | 300 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -43.3% | -3.7% |
| % Gain to Breakeven | 76.3% | 3.9% |
| Time to Breakeven | 100 days | 6 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -35.7% | -6.8% |
| % Gain to Breakeven | 55.5% | 7.3% |
| Time to Breakeven | 87 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -22.7% | -0.2% |
| % Gain to Breakeven | 29.4% | 0.2% |
| Time to Breakeven | 21 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -99.3% | -17.9% |
| % Gain to Breakeven | 14900.0% | 21.8% |
| Time to Breakeven | 71 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -49.5% | -53.4% |
| % Gain to Breakeven | 98.0% | 114.4% |
| Time to Breakeven | 69 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -44.0% | -8.6% |
| % Gain to Breakeven | 78.6% | 9.5% |
| Time to Breakeven | 671 days | 47 days |
In The Past
TherapeuticsMD's stock fell -28.9% during the 2025 US Tariff Shock. Such a loss loss requires a 40.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About TherapeuticsMD (TXMD)
TherapeuticsMD, Inc. (TXMD) is a U.S.-based women's healthcare company dedicated to developing and commercializing pharmaceutical products addressing significant health needs for women. The company focuses on bringing FDA-approved therapies to market, primarily in areas such as hormone therapy and contraception, while also maintaining a pipeline of investigational drug candidates for future growth.
The company's main commercialized products include IMVEXXY, used for the treatment of moderate-to-severe dyspareunia (painful intercourse); BIJUVA, a bio-identical hormone therapy for moderate-to-severe vasomotor symptoms (hot flashes and night sweats); and ANNOVERA, a novel ring-shaped contraceptive vaginal system. In addition to these prescription pharmaceuticals, TherapeuticsMD also manufactures and distributes a portfolio of branded and generic prescription prenatal vitamins under various brand names.
TherapeuticsMD primarily serves the market of women in the United States, targeting those experiencing specific health conditions related to menopause, contraception, and pregnancy. The company sells its prescription pharmaceutical products and prenatal vitamins to wholesale distributors and retail pharmacy distributors, who then supply the products to pharmacies and ultimately to patients.
AI Analysis | Feedback
1. A women's health pharmaceutical company, similar to a specialized division of Bayer focusing on hormone therapy and contraception.
2. Like a smaller, more focused Organon, dedicated to developing and selling prescription products for women's hormonal health and reproductive needs.
AI Analysis | Feedback
- IMVEXXY: A treatment for moderate-to-severe dyspareunia.
- BIJUVA: A bio-identical hormone therapy for moderate-to-severe vasomotor symptoms.
- ANNOVERA: A ring-shaped contraceptive vaginal system.
- Prenatal Vitamins: Branded and generic prescription prenatal vitamins under various brands (e.g., vitaTrue, vitaPearl).
AI Analysis | Feedback
TherapeuticsMD (TXMD) sells its products primarily to other companies. Based on the provided description, its major customers are:
- Wholesale distributors
- Retail pharmacy distributors
AI Analysis | Feedback
- Amneal Pharmaceuticals, Inc. (AMRX)
- Thermo Fisher Scientific Inc. (TMO)
- LTS Lohmann Therapie-Systeme AG
AI Analysis | Feedback
Marlan Walker – Chief Executive Officer
Marlan Walker has served as the Chief Executive Officer of TherapeuticsMD, Inc. since December 2022. He joined TherapeuticsMD in 2013 and held various roles, including General Counsel from March 2016 until 2023, Chief Development Officer from April 2018 to December 2019, and Corporate and Intellectual Property Counsel from June 2013 to March 2016. Prior to joining TherapeuticsMD, Mr. Walker was Intellectual Property Counsel at Medicis Pharmaceutical Corp. from June 2011 to December 2012. Medicis Pharmaceutical Corp. was subsequently acquired by Valeant Pharmaceutical International, Inc. in December 2012. His legal experience also includes positions at law firms such as Kilpatrick Townsend & Stockton, Luce Forward Hamilton & Scripps, and Greenberg Traurig, LLP.
Joseph Ziegler – Principal Financial and Accounting Officer
Joseph Ziegler has served as the Principal Financial and Accounting Officer of TherapeuticsMD, Inc. since August 2023. He is also the founder and Chief Executive Officer of JZ Advisory Group, a consulting company established in January 2022, which focuses on providing fractional CFO and outsourced accounting services. Mr. Ziegler has extensive experience in the healthcare industry, having held multiple CFO roles, including for private equity-backed companies such as Biomatrix and Novis Pharmaceuticals. He previously served as a director of Progressive Care Inc. from December 2021 until December 2024. He holds a B.S. in Finance and an M.B.A. from Florida Atlantic University.
Marlan Walker has served as the Chief Executive Officer of TherapeuticsMD, Inc. since December 2022. He joined TherapeuticsMD in 2013 and held various roles, including General Counsel from March 2016 until 2023, Chief Development Officer from April 2018 to December 2019, and Corporate and Intellectual Property Counsel from June 2013 to March 2016. Prior to joining TherapeuticsMD, Mr. Walker was Intellectual Property Counsel at Medicis Pharmaceutical Corp. from June 2011 to December 2012. Medicis Pharmaceutical Corp. was subsequently acquired by Valeant Pharmaceutical International, Inc. in December 2012. His legal experience also includes positions at law firms such as Kilpatrick Townsend & Stockton, Luce Forward Hamilton & Scripps, and Greenberg Traurig, LLP.
Joseph Ziegler – Principal Financial and Accounting Officer
Joseph Ziegler has served as the Principal Financial and Accounting Officer of TherapeuticsMD, Inc. since August 2023. He is also the founder and Chief Executive Officer of JZ Advisory Group, a consulting company established in January 2022, which focuses on providing fractional CFO and outsourced accounting services. Mr. Ziegler has extensive experience in the healthcare industry, having held multiple CFO roles, including for private equity-backed companies such as Biomatrix and Novis Pharmaceuticals. He previously served as a director of Progressive Care Inc. from December 2021 until December 2024. He holds a B.S. in Finance and an M.B.A. from Florida Atlantic University.
AI Analysis | Feedback
The primary key risks for TherapeuticsMD (TXMD), a pharmaceutical royalty company, are directly tied to its reliance on licensing agreements and its financial health.
- Breach of Contract Lawsuit Against Mayne Pharma: TherapeuticsMD has filed a breach of contract lawsuit against Mayne Pharma, which poses a significant risk to the company's primary royalty revenue stream. This litigation pattern suggests deteriorating business relationships that could materially impact TherapeuticsMD's financial performance.
- Dependence on Mayne Pharma's Commercialization Performance: As a pharmaceutical royalty company, TherapeuticsMD's revenue is almost entirely dependent on Mayne Pharma's net sales of licensed products, including IMVEXXY, BIJUVA, and ANNOVERA. Should Mayne Pharma's commercialization efforts falter due to competition, market dynamics, or operational challenges, TherapeuticsMD's royalty income would be directly and negatively affected.
- Financial Instability and Limited Liquidity: TherapeuticsMD faces significant financial health and liquidity risks, evidenced by ongoing severe financial losses, a relatively small market capitalization, and limited cash holdings. The company's financial indicators, such as a low GF Score and an Altman Z-Score in the distress zone, point to potential financial instability. The company is actively exploring strategic options to enhance its operations, including potential acquisitions and mergers.
AI Analysis | Feedback
null
AI Analysis | Feedback
TherapeuticsMD (symbol: TXMD) operates in several addressable markets with its main products:
- IMVEXXY (for the treatment of moderate-to-severe dyspareunia): The U.S. dyspareunia treatment market was valued at approximately USD 231.45 million in 2025 and is projected to grow to USD 1,162.49 million by 2033, exhibiting a compound annual growth rate (CAGR) of 4.90% from 2025 to 2033. Globally, the dyspareunia treatment market was estimated at USD 792.84 million in 2025.
- BIJUVA (bio-identical hormone therapy for the treatment of moderate-to-severe vasomotor symptoms): The global vasomotor menopausal symptoms (VMS) treatment market was valued at USD 18.85 billion in 2024 and is expected to reach USD 30.50 billion by 2032, with a CAGR of 6.20%. The U.S. vasomotor menopausal symptoms (VMS) treatment market held the largest revenue share of 71% in 2024 within North America.
- ANNOVERA (ring-shaped contraceptive vaginal system): The U.S. contraceptive market size was exhibited at USD 10.85 billion in 2025 and is projected to reach approximately USD 18.94 billion by 2035, growing at a CAGR of 5.73% during the forecast period from 2026 to 2035. The global contraceptive devices market was valued at US$12.9 billion in 2021 and is expected to reach US$23.72 billion in 2030.
AI Analysis | Feedback
TherapeuticsMD (TXMD) has transitioned to a pharmaceutical royalty-based business model, focusing on collecting royalties from its licensees rather than direct research, development, or commercial operations. This shift, which occurred in December 2022, redefines the drivers of its future revenue growth.
Based on this model, the expected drivers of TherapeuticsMD's future revenue growth over the next 2-3 years include:
- Increased Sales of Licensed Products by Mayne Pharma: TherapeuticsMD's primary revenue source comes from royalties on the sales of its key women's healthcare products, IMVEXXY, BIJUVA, and ANNOVERA, which are commercialized by its licensee, Mayne Pharma. Therefore, any growth in Mayne Pharma's sales volume or market penetration of these products will directly lead to increased license revenue for TherapeuticsMD. Recent financial reports have indicated an increase in license revenue, primarily from the Mayne License Agreement.
- Strategic Alternatives and New Licensing Opportunities: TherapeuticsMD is actively evaluating strategic alternatives, including potential acquisitions or mergers. While a timeline has not been set, such strategic moves could introduce new royalty streams or optimize existing agreements, thereby contributing to future revenue growth.
- Favorable Market Trends in Women's Healthcare: Broader positive trends in the women's healthcare market, particularly in areas addressed by IMVEXXY (for moderate-to-severe dyspareunia), BIJUVA (for moderate-to-severe vasomotor symptoms), and ANNOVERA (contraception), could lead to increased demand. This heightened demand would likely translate into higher sales for Mayne Pharma and, consequently, greater royalty payments to TherapeuticsMD.
AI Analysis | Feedback
Share Issuance
- TherapeuticsMD's shares outstanding increased by 1.31% in one year, with 11.57 million shares outstanding as of Q3 2025.
- The company executed a stock split on May 9, 2022, as one of three splits in its history.
Inbound Investments
- TherapeuticsMD transitioned to a pharmaceutical royalty company, receiving royalties from licensed products.
- The company granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA, and prenatal vitamin products in the United States, and assigned its exclusive license to Mayne Pharma for ANNOVERA in the U.S.
Capital Expenditures
- TherapeuticsMD reported $0 in capital expenditures in Q3 2022.
- Some recent financial reports indicate "n/a" for capital expenditures, suggesting minimal or no significant spending in this category.
Peer Outperformance in Pharmaceuticals
TXMD has trailed 82% of its 60 Pharmaceuticals peers over 5Y. Among the peers that beat it are CORT and ACAD. Pharmaceuticals ranks 6th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Pharmaceuticals constituents that TXMD has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
92%
of 71 industry peers · 89.4% return
3Y
33%
of 67 industry peers · -26.2% return
5Y
18%
of 60 industry peers · -94.5% return
Pharmaceuticals peers with revenue growth within 4pp of TXMD's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| TXMD | TherapeuticsMD | 28.7% | -105.1x | 89.4% | -26.2% | -94.5% | — |
| CORT | Corcept Therapeutics | 24.9% | 216.5x | 47.6% | 303.6% | 465.7% | +560pp |
| ACAD | Acadia Pharmaceuticals | 29.3% | 8.9x | -9.3% | -17.1% | 12.6% | +107pp |
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Pharmaceuticals is TXMD's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.3% | 52.8% | 104.0% | CAH 479% · MCK 401% · COR 196% |
| Health Care Services | 20 | 20.2% | 39.3% | 14.5% | HIMS 232% · RDNT 145% · DGX 85% |
| Managed Health Care | 8 | 45.5% | -1.8% | 5.4% | OSCR 117% · HQY 46% · ELV 17% |
| Health Care Facilities | 24 | 3.1% | 17.0% | 4.6% | THC 333% · NHC 288% · ENSG 147% |
| Health Care Equipment | 50 | -2.1% | 3.1% | -13.1% | UFPT 366% · GKOS 269% · TMDX 184% |
| Pharmaceuticals ← | 61 | -13.2% | -1.4% | -31.7% | LQDA 961% · KNSA 589% · CORT 466% |
| Health Care Supplies | 12 | 25.3% | -5.0% | -34.3% | LNTH 330% · HAE 73% · MMSI 29% |
| Life Sciences Tools & Services | 109 | -17.2% | -10.2% | -66.7% | NTRA 265% · MEDP 230% · GH 60% |
| Biotechnology | 363 | -27.2% | -29.9% | -81.8% | DNTH 1011% · ELVN 973% · ADMA 875% |
| Health Care Technology | 22 | -33.2% | -63.0% | -83.5% | VEEV -4% · DOCS -57% |
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| TherapeuticsMD Earnings Notes | 12/16/2025 | |
| How Low Can TherapeuticsMD Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 21.59 |
| Mkt Cap | 85.7 |
| Rev LTM | 34,911 |
| Op Inc LTM | 4,074 |
| FCF LTM | 5,710 |
| FCF 3Y Avg | 4,989 |
| CFO LTM | 7,069 |
| CFO 3Y Avg | 6,537 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.5% |
| Rev Chg 3Y Avg | 4.5% |
| Rev Chg Q | 3.8% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Inc Chg LTM | -1.5% |
| Op Inc Chg 3Y Avg | 23.1% |
| Op Mgn LTM | 14.7% |
| Op Mgn 3Y Avg | 20.5% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 25.5% |
| CFO/Rev 3Y Avg | 19.7% |
| FCF/Rev LTM | 20.7% |
| FCF/Rev 3Y Avg | 15.1% |
Price Behavior
Price Behavior
| Market Price | $1.97 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -28.9% | |
| 50 Days | 200 Days | |
| DMA Price | $2.10 | $2.12 |
| DMA Trend | indeterminate | up |
| Distance from DMA | -6.3% | -7.2% |
| 3M | 1YR | |
| Volatility | 33.3% | 76.2% |
| Downside Capture | 39.99 | 29.44 |
| Upside Capture | 19.25 | 102.11 |
| Correlation (S&P 500) | -8.1% | 2.4% |
TXMD Betas & Captures as of 9/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.31 | -0.06 | -0.52 | -0.09 | 0.17 | 0.65 |
| Up Beta | -4.14 | -2.05 | -1.60 | -0.09 | -0.67 | 0.51 |
| Down Beta | -0.22 | -0.01 | -0.86 | 0.13 | -0.15 | 0.68 |
| Up Capture | -35% | 49% | -28% | -13% | 85% | 27% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 7 | 15 | 21 | 49 | 109 | 311 |
| Down Capture | 107% | 62% | 18% | -34% | 25% | 98% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 12 | 16 | 26 | 54 | 110 | 361 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TXMD | |
|---|---|---|---|---|
| TXMD | 86.0% | 76.3% | 1.13 | - |
| Sector ETF (XLV) | 23.9% | 16.0% | 1.14 | 13.7% |
| Equity (SPY) | 17.6% | 12.7% | 0.99 | 2.6% |
| Gold (GLD) | 0.5% | 29.5% | 0.02 | 2.4% |
| Commodities (DBC) | 50.9% | 20.7% | 1.88 | -2.8% |
| Real Estate (VNQ) | 4.7% | 13.7% | 0.08 | 15.4% |
| Bitcoin (BTCUSD) | -28.1% | 43.7% | -0.63 | -9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TXMD | |
|---|---|---|---|---|
| TXMD | -44.4% | 189.1% | 0.12 | - |
| Sector ETF (XLV) | 8.1% | 15.2% | 0.34 | 3.7% |
| Equity (SPY) | 13.4% | 17.1% | 0.60 | 7.7% |
| Gold (GLD) | 18.5% | 18.9% | 0.79 | -1.3% |
| Commodities (DBC) | 9.7% | 19.5% | 0.38 | -2.0% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 5.5% |
| Bitcoin (BTCUSD) | 8.7% | 51.8% | 0.35 | 16.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TXMD | |
|---|---|---|---|---|
| TXMD | -40.5% | 145.8% | 0.03 | - |
| Sector ETF (XLV) | 11.0% | 16.7% | 0.54 | 11.7% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 14.9% |
| Gold (GLD) | 12.2% | 16.4% | 0.61 | -0.9% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 3.1% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 12.6% |
| Bitcoin (BTCUSD) | 63.1% | 66.2% | 1.03 | 11.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/14/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | 0.5% | -2.9% | 1.4% |
| 5/12/2026 | 3.6% | 4.6% | -6.7% |
| 11/13/2025 | -3.6% | -1.8% | 1.2% |
| 8/12/2025 | 5.0% | 5.0% | 0.5% |
| 5/13/2025 | -3.9% | -2.0% | -21.1% |
| 3/27/2025 | -6.5% | -7.6% | 16.2% |
| 11/12/2024 | -0.2% | -13.3% | -16.7% |
| 8/12/2024 | 2.4% | -1.2% | 6.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 6 | 9 |
| # Negative | 11 | 15 | 12 |
| Median Positive | 2.4% | 6.7% | 6.5% |
| Median Negative | -6.5% | -6.6% | -12.5% |
| Max Positive | 24.6% | 38.6% | 215.9% |
| Max Negative | -27.5% | -29.4% | -39.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | 0.5% | -2.9% | 1.4% |
| 5/12/2026 | 3.6% | 4.6% | -6.7% |
| 11/13/2025 | -3.6% | -1.8% | 1.2% |
| 8/12/2025 | 5.0% | 5.0% | 0.5% |
| 5/13/2025 | -3.9% | -2.0% | -21.1% |
| 3/27/2025 | -6.5% | -7.6% | 16.2% |
| 11/12/2024 | -0.2% | -13.3% | -16.7% |
| 8/12/2024 | 2.4% | -1.2% | 6.5% |
| 5/10/2024 | 2.5% | 9.4% | 2.5% |
| 11/14/2023 | 17.4% | 38.6% | 18.9% |
| 8/14/2023 | -2.8% | -5.3% | -8.6% |
| 5/15/2023 | 0.2% | -1.8% | -13.9% |
| 11/14/2022 | -8.2% | -29.4% | 8.4% |
| 8/15/2022 | 0.3% | 8.5% | -11.1% |
| 5/16/2022 | -14.0% | -18.5% | 215.9% |
| 3/10/2022 | -27.5% | -8.8% | -14.7% |
| 11/12/2021 | -4.7% | -11.5% | -39.5% |
| 8/4/2021 | -6.7% | -6.2% | -18.9% |
| 5/6/2021 | -13.3% | -20.3% | -5.5% |
| 3/2/2021 | 0.3% | -6.6% | -7.3% |
| 11/9/2020 | 24.6% | 0.8% | -0.8% |
| SUMMARY STATS | |||
| # Positive | 10 | 6 | 9 |
| # Negative | 11 | 15 | 12 |
| Median Positive | 2.4% | 6.7% | 6.5% |
| Median Negative | -6.5% | -6.6% | -12.5% |
| Max Positive | 24.6% | 38.6% | 215.9% |
| Max Negative | -27.5% | -29.4% | -39.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 04/07/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 04/07/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/23/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/04/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 03/04/2021 | 10-K |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/07/2020 | 10-Q |
| 03/31/2020 | 05/06/2020 | 10-Q |
| 12/31/2019 | 02/24/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Thompson, Tommy G | Direct | Buy | 12292025 | 1.67 | 8,400 | 14,031 | 38,716 | Form | |
| 2 | Thompson, Tommy G | Direct | Buy | 4152025 | 1.00 | 325 | 326 | 14,806 | Form | |
| 3 | Walker, Marlan D | Chief Executive Officer | Direct | Buy | 4152025 | 1.00 | 490 | 489 | 73,529 | Form |
| 4 | Walker, Marlan D | Chief Executive Officer | Direct | Buy | 4102025 | 0.86 | 1,167 | 1,000 | 62,703 | Form |
| 5 | Walker, Marlan D | Chief Executive Officer | Direct | Buy | 4102025 | 0.87 | 1,136 | 994 | 62,963 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Thompson, Tommy G | Direct | Buy | 12292025 | 1.67 | 8,400 | 14,031 | 38,716 | Form | |
| 2 | Thompson, Tommy G | Direct | Buy | 4152025 | 1.00 | 325 | 326 | 14,806 | Form | |
| 3 | Walker, Marlan D | Chief Executive Officer | Direct | Buy | 4152025 | 1.00 | 490 | 489 | 73,529 | Form |
| 4 | Walker, Marlan D | Chief Executive Officer | Direct | Buy | 4102025 | 0.86 | 1,167 | 1,000 | 62,703 | Form |
| 5 | Walker, Marlan D | Chief Executive Officer | Direct | Buy | 4102025 | 0.87 | 1,136 | 994 | 62,963 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 10/15/2026